Nektar Therapeutics (NKTR)
NASDAQ: NKTR
· Real-Time Price · USD
58.50
2.88 (5.18%)
At close: Sep 26, 2025, 3:59 PM
58.10
-0.68%
After-hours: Sep 26, 2025, 07:54 PM EDT
Nektar Therapeutics Revenue Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Non Cash Royalty Revenue Related To Sale Of Future Royalties Revenue | 11.18M | 10.46M | 33.03M | 15.73M | 16.79M | 15.51M | 18.06M | 18.17M | 15.83M | 16.86M | 17.63M | 18.34M | 16.26M | 17.56M | 19.08M | 19.41M | 20.46M | 18.8M | 20.56M | 10.42M | 7.68M | 9.89M | 8.72M | 10.26M | 9.09M | 8.23M | 8.97M | 8.37M | 9.04M |
| Non Cash Royalty Revenue Related To Sale Of Future Royalties Revenue Growth | +6.84% | -68.33% | +109.95% | -6.31% | +8.27% | -14.14% | -0.58% | +14.75% | -6.10% | -4.35% | -3.90% | +12.78% | -7.39% | -7.96% | -1.72% | -5.10% | +8.82% | -8.58% | +97.29% | +35.63% | -22.34% | +13.50% | -15.06% | +12.90% | +10.46% | -8.26% | +7.15% | -7.44% | n/a |
Operating Expense Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 17.07M | 24.35M | 17.14M | 18.96M | 20.51M | 20.15M | 17.32M | 21.15M | 17.87M | 21.08M | 21.94M | 22.53M | 20.52M | 27.34M | 32.14M | 29.47M | 29.55M | 31.68M | 27.14M | 26.98M | 24.35M | 26.22M | 27.14M | 23.98M | 22.58M | 25.01M | 23.78M | 18.72M | 20.26M | 18.69M | 12.34M | 12.05M | 16M | 11.98M | 12.76M | 10.25M | 11.04M | 10.23M | 13.23M | 9.54M | 10.18M | 10.3M |
| Selling, General, and Administrative Revenue Growth | -29.88% | +42.08% | -9.61% | -7.57% | +1.79% | +16.33% | -18.10% | +18.34% | -15.24% | -3.91% | -2.64% | +9.81% | -24.94% | -14.94% | +9.07% | -0.29% | -6.70% | +16.74% | +0.57% | +10.82% | -7.13% | -3.41% | +13.17% | +6.21% | -9.70% | +5.17% | +27.03% | -7.62% | +8.42% | +51.47% | +2.34% | -24.64% | +33.57% | -6.14% | +24.45% | -7.09% | +7.89% | -22.72% | +38.67% | -6.28% | -1.16% | n/a |
| Research and Development Revenue | 29.89M | 30.48M | 28.75M | 35.03M | 29.72M | 27.41M | 29.94M | 24.07M | 29.68M | 30.47M | 34.74M | 33.59M | 42.74M | 107.25M | 99.61M | 103.74M | 101.31M | 95.6M | 102.72M | 100.53M | 96.44M | 108.99M | 110.37M | 99.05M | 106.69M | 118.46M | 108.88M | 102.89M | 88.33M | 99.42M | 81.43M | 65.71M | 60.26M | 61.06M | 50.23M | 51.95M | 52.35M | 49.27M | 47.13M | 43.23M | 45.41M | 47.01M |
| Research and Development Revenue Growth | -1.95% | +6.04% | -17.94% | +17.85% | +8.45% | -8.46% | +24.40% | -18.90% | -2.59% | -12.29% | +3.42% | -21.41% | -60.15% | +7.67% | -3.98% | +2.39% | +5.97% | -6.93% | +2.18% | +4.25% | -11.52% | -1.25% | +11.43% | -7.16% | -9.94% | +8.80% | +5.82% | +16.48% | -11.15% | +22.10% | +23.91% | +9.05% | -1.31% | +21.55% | -3.31% | -0.76% | +6.26% | +4.53% | +9.04% | -4.81% | -3.40% | n/a |